Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hoya ConBio and Hornbrook Group expand alliance
Under the terms of the agreement, Hoya ConBio lasers will be a staple at all Hornbrook Group courses through 2009 at their Center for Advanced Clinical Education in
Under the terms of the agreement, Hoya ConBio lasers will be a staple at all Hornbrook Group courses through 2009 at their Center for Advanced Clinical Education in
This trial was designed to assess the safety, tolerability and preliminary efficacy of Optisomal encapsulated Alocrest. Preliminary results show that Alocrest was generally well tolerated with acceptable and
Thallion has agreed to conduct certain additional animal studies concurrent with the US clinical study, the results of which will be submitted to the FDA in advance of
The SBIR grants awarded by the National Heart, Lung, and Blood Institute of the National Institutes of Health and the US Army will fund advancements in the Ibis
The agency concurs that a single Phase III pivotal trial should provide confirmatory evidence if the clinical and statistical benefits shown in the study are compelling. Jack Stover,
The two peptides, CGEN-856 and CGEN-857 were identified using the company’s previously announced GPCR ligand discovery platform. In an in-vivo model of cardiac remodeling, CGEN-856 and CGEN-857 were
The SameSpots software provides significant improvements in speed, objectivity and statistical power. This is said to make a radical impact on proteomics research by giving customers both the
The acquisition advances Intertek’s strategic growth in expert support services to the global pharmaceutical, medical device and drug delivery industry. BioClin will operate in Intertek’s Pharmaceutical Services Group
The US District Court jury in Marshall, Texas has found that the company’s Taxus Express and Taxus Liberte drug-eluting stent products infringe Saffran’s patent and that the patent
Under the terms of the new agreement, NascaCell receives non-exclusive rights to uses of aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug